Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), are associated with metabolic abnormalities...Previously, we have reported that the combined metabolic activators (CMA), which include the precursors of nicotinamide adenine dinucleotide [including nicotinamide riboside] and glutathione, can be utilized to alleviate metabolic disorders by activating mitochondrial metabolism...mitochondrial dysfunction is involved in the underlying molecular pathways of Alzheimer's Disease...We showed that combined metabolic activators administration significantly improved behavioural scores in parallel with the neurohistological outcomes in the Alzheimer's Disease and Parkinson's Disease animal models and is a promising treatment for improving the metabolic parameters and brain functions in neurodegenerative diseases.